生殖医学杂志

参考文献

[1] Schindler AE.Progestational effects of dydrogesterone in vitro,in vivo and on the human endometrium[J].Maturitas,2009,65(suppl 1):S3–S11.

[2] Schindler AE.Present and future aspects of dydrogesterone in prevention or treatment of pregnancy disorders:an outlook[J].Horm Mol Biol Clin Investig,2016,27:49-53.

[3] Griesinger G,Tournaye H,Macklon N,et al.Dydrogesterone:pharmacological profile and mechanism of action as luteal phase support in assisted reproduction[J/OL].Reprod Biomed Online,2019,38:249-259.

[4] Wahabi HA,Fayed AA,Esmaeil SA,et al.Progestogen for treating threatened miscarriage[J].Cochrane Database Syst Rev,2018,(8):CD005943.

[5] Saccone G,Schoen C,Franasiak JM,et al.Supplementation with progestogens in the first trimester of pregnancy to prevent miscarriage in women with unexplained recurrent miscarriage:a systematic review and meta-analysis of randomized,controlled trials[J].Fertil Steril,2017,107:430-438.

[6] Ciampaglia W,Cognigni GE.Clinical use of progesterone in infertility and assisted reproduction[J].Acta Obstet Gynecol Scand,2015,94:17-27.

[7] Raghupathy R,Szekeres-Bartho J.Dydrogesterone and the immunology of pregnancy[J].Horm Mol Biol Clin Investig,2016,27:63-71.

[8] Check JH,DiAntonio G,DiAntonio A,et al.The progesterone receptor antagonist mifepristone does not lower surum progesterone induced blockong factor (PIBF) in the presence of progesterone[J].Clin Exp Obstet Gynecol,2016,43:189-191.

[9] Shapiro D,Boostanfar R,Silverberg K,et al.Examining the evidence:progesterone supplementation during fresh and frozen embryo transfer[J/OL].Reprod Biomed Online,2014,29(suppl 1):S1-S14.

[10] Beltsos AN,Sanchez MD,Doody KJ,et al.Patients' administration pprogesterone vaginal insert (Endometrin■) compared to intramuscular progesterone for luteal phase support[J].Reprod Health,2014,11:78.

[11] Vaisbuch E,Leong M,Shoham Z.Progesterone support in IVF:is evidence-based medicine translated to clinical practice?A worldwide web-based survey[J/OL].Reprod Biomed Online,2012,25:139-145.

[12] 孙赟,刘平,叶虹,等.黄体支持与孕激素补充共识[J].生殖与避孕,2015,25:1-8.

[13] Stanczyk FZ,Hapgood JP,Winer S,et al.Progestogens used in postmenopausal hormone therapy:differences in their pharmacological properties,intracellular actions,and clinical effects[J].Endocr Rev,2013,34:171-208.

[14] 胡兴韶,封全灵.地屈孕酮与黄体酮治疗先兆流产效果比较的Meta分析[J].中国基层医药,2017,24:988-991.

[15] Lee HJ,Park TC,Kim JH,et al.The influence of oral dydrogesterone and vaginal progesterone on threatened abortion:a systematic review and meta-analysis[J].Biomed Res Int,2017,2017:3616875.

[16] Carp H.A systematic review of dydrogesterone for the treatment of recurrent miscarriage[J].Gynecol Endocrinol,2015,31:422-430.

[17] Tomic V,Kasum M,Vucic K.The role of luteal support during IVF:a qualitative systematic review[J].Gynecol Endocrinol,2019,29:1-6.

[18] Tournaye H,Sukhikh GT,Kahler,et al.A Phase III randomized controlled trial comparing the efficacy,safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization[J].Hum Reprod,2017,32:1019-1027.

[19] Griesinger G,Blockeel C,Sukhikh GT,et al.Oral dydrogesterone versus intravaginal micronized progesterone gel for luteal phase support in IVF:a randomized clinical trial[J].Hum Reprod,2018,33:2212-2221.

[20] Carp HJ.Progestogens in the prevention of miscarriage[J].Horm Mol Biol Clin Investig,2016,27:55-62.

[21] Manuck TA.Pharmacogenomics of preterm birth prevention and treatment[J].BJOG,2016,123:368-375.

[22] Schindler AE.Progestogens and pregancy disorders[J].Giorn It Ost Gin,2015,37:35-37.

[23] Zainul Rashid MR,Lim JF,Nawawi NH,et al.A pilot study to determine whether progestogen supplementation using dydrogesterone during the first trimester will reduce the incidence of gestational hypertension in primigravidae[J].Gynecol Endocrinol,2014,30:217-220.

[24] Ali AB,Ahmad MF,Kwang NB,et al.Dydrogesterone support following assisted reproductive technique(ART)reduces the risk of pre-eclampsia[J].Horm Mol Biol Clin Investig,2016,27:93-96.

[25] Wadhwa L,Batra S,Tempe A.Role of dydrogesterone in the treatment of idiopathic IUGR[J].Int J Reprod Contracept Obstet Gynecol,2013,2:157-160.

[26] Mohamad Razi ZR,Schindler AE.Review on role of progestogen (dydrogesterone) in the prevention of gestational hypertension[J].Horm Mol Biol Clin Investig,2016,27:73-76.

[27] Queisser-Luft A.Dydrogesterone use during pregnancy:overview of birth defects reported since 1977[J].Early Hum Dev,2009,85:375-377.

[28] Nadarajah R,Rajesh H,Wong KY,et al.Live birth rates and safety profile using dydrogesterone for luteal phase support in assisted reproductive techniques[J].Singapore Med J,2017,58:294-297.

[29] Huang J,Xie Q,Lin J,et al.Neonatal outcomes and congenital malformations in children born after dydrogesterone application in progestin-primed ovarian stimulation protocol for IVF:a retrospective cohort study[J].Drug Des Devel Ther,2019,13:2553-2563.

[30] Zaqout M,Aslem E,Abuqamar M,et al.The impact of oral intake of dydrogesterone on fetal heart development during early pregnancy[J].Pediatr Cardiol,2015,36:1483-1488.

[31] Cedergren MI,Selbing AJ,K?llén BA.Risk factors for cardiovascular malformation-a study based on prospectively collected data[J].Scand J Work Environ Health,2002,28:12-17.

[32] Koren G,Gilboa D,Katz R.Fetal safety of dydrogesterone exposure in the first trimester of pregnancy[J].Clin Drug Investig,2019,Oct 3.doi:10.1007/s40261-019-00862-w.